Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTOT-24: Lulizumab Pegol in Kidney Transplantation
NCT04066114Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2019
- Primary completion
- Sep 2023
- Modality
- Antibody Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of lulizumab pegol in kidney transplant rejection, sponsored by National Institute of Allergy and Infectious Diseases. Started Dec 2019; status: completed.
02
Drugs
lulizumab pegol
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT04066114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04066114.